1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Colorado >
  6. Travere Therapeutics Acquires Manchester Pharmaceuticals

M&A Deal Summary

Travere Therapeutics Acquires Manchester Pharmaceuticals

On February 12, 2014, Travere Therapeutics acquired life science company Manchester Pharmaceuticals for 63M USD

Acquisition Highlights
  • This is Travere Therapeutics’ 2nd transaction in the Life Science sector.
  • This is Travere Therapeutics’ largest (disclosed) transaction.
  • This is Travere Therapeutics’ 2nd transaction in the United States.
  • This is Travere Therapeutics’ 1st transaction in Colorado.

M&A Deal Summary
Date 2014-02-12
Target Manchester Pharmaceuticals
Sector Life Science
Buyer(s) Travere Therapeutics
Deal Type Add-on Acquisition
Deal Value 63M USD

Target

Manchester Pharmaceuticals

Fort Collins, Colorado, United States
Manchester Pharmaceuticals is a privately-held specialty pharmaceutical company, is focused on the identification, development, and commercialization of therapeutic modalities to address the special needs of patients with ultra-rare diseases. Manchester markets Chenodal (chenodiol tablets) and Vecamyl® (mecamylamine tablets) in the U.S. Manchester's founders and management have extensive combined experience in the rare disease market.

Search 214,503 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Travere Therapeutics

San Diego, California, United States
Category Company
Founded 2011
Sector Life Science
Employees385
Revenue 233M USD (2024)
DESCRIPTION

Travere Therapeutics is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. Travere Therapeutics was founded in 2011 and is based in San Diego, California.

DEAL STATS #
Overall 2 of 3
Sector: Life Science M&A 2 of 3
Type: Add-on Acquisition M&A Deals 2 of 2
State: Colorado M&A 1 of 1
Country: United States M&A 2 of 3
Year: 2014 M&A 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-12-12 Kyalin Biosciences

Encinitas, California, United States

Kyalin Biosciences, Inc. is an early-stage company, that is developing therapies targeting the core symptoms of autism and related conditions. Its lead product is an optimized intranasal delivery form of carbetocin, a synthetic analog of the naturally occurring peptide hormone, oxytocin. Kyalin Biosciences develops therapies targeting the core symptoms of autism and related conditions. While autism affects 1 in 88 children in the U.S.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-06-20 Asklepion - Liquid Formulation Of Ursodeoxycholic Acid

United States

Asklepion - Liquid Formulation Of Ursodeoxycholic Acid also known as ursodiol or UDCA, ursodeoxycholic acid is a naturally occurring hydrophilic bile acid derived from cholesterol, which is indicated for the treatment of PBC and currently prescribed only in solid forms. Introducing a liquid formulation of ursodeoxycholic acid would provide healthcare professionals with a dosing alternative for patients who have difficulty swallowing tablets or capsules, and may facilitate increased compliance.

Buy -
Mergr

Solution for

Product

Company

Legal